This week, because April 11 is World Parkinson’s Day, we chat with Dieter Willbold, CSO of Priavoid, and Antje Willuweit, director preclinical development of Priavoid, and Karsten Eastman, CEO and co-founder of Sethera Therapeutics, about the company’s work on peptides.

Times:

02:52 Sethera Therapeutics

22:35 Priavoid

Priavoid

Priavoid, a company advancing novel disease-modifying approaches for neurodegenerative disorders, recently presented preclinical proof-of-concept data for its candidate PRI-101 in Parkinson’s disease (PD) and related synucleinopathies.

The results show that PRI-101 inhibited aggregation of α-synuclein (α-syn) and actively disassembled α-syn-fibrils across in vitro and in vivo models relevant to P ...